BG61123B2 - Бициклични карбоксилни киселини и техни алкилни и аралкилни естери - Google Patents

Бициклични карбоксилни киселини и техни алкилни и аралкилни естери Download PDF

Info

Publication number: BG61123B2
Authority: BG; Bulgaria
Prior art keywords: diazepine; dioxo; carboxylic acid; pyridazo; octahydro
Prior art date: 1982-05-12

Application number

BG098502A

Other languages

Bulgarian (bg)

English (en)

Inventor

Michael Attwood

Cedric Hassall

Robert Lambert

Geoffrey Lawton

Sally Redshaw

Original Assignee

F. Hoffmann - La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-05-12

Filing date

1994-02-21

Publication date

1996-11-29

1994-02-21 Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag

1996-11-29 Publication of BG61123B2 publication Critical patent/BG61123B2/bg

Links

125000000217 alkyl group Chemical group 0.000 title claims abstract description 22
125000003710 aryl alkyl group Chemical group 0.000 title claims abstract description 13
-1 Bicyclic carboxylic acids Chemical class 0.000 title claims description 95
150000001875 compounds Chemical class 0.000 claims abstract description 172
125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 47
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 43
150000003839 salts Chemical class 0.000 claims abstract description 24
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 21
239000001257 hydrogen Substances 0.000 claims abstract description 21
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract description 12
239000005977 Ethylene Substances 0.000 claims abstract description 12
150000002431 hydrogen Chemical class 0.000 claims abstract description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 10
125000004103 aminoalkyl group Chemical group 0.000 claims abstract description 9
125000004043 oxo group Chemical group O=* 0.000 claims abstract description 8
125000004985 dialkyl amino alkyl group Chemical group 0.000 claims abstract description 6
125000005154 alkyl sulfonyl amino alkyl group Chemical group 0.000 claims abstract description 5
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims abstract description 4
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 47
239000002253 acid Substances 0.000 claims description 38
238000000034 method Methods 0.000 claims description 38
239000000203 mixture Substances 0.000 claims description 34
QRKPPWPLSQRGSU-UHFFFAOYSA-N diazepine-1-carboxylic acid Chemical compound OC(=O)N1C=CC=CC=N1 QRKPPWPLSQRGSU-UHFFFAOYSA-N 0.000 claims description 33
238000002360 preparation method Methods 0.000 claims description 17
WYRQJCWZHMEHOX-UHFFFAOYSA-N tert-butyl diazepine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CC=CC=N1 WYRQJCWZHMEHOX-UHFFFAOYSA-N 0.000 claims description 10
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
125000006308 propyl amino group Chemical group 0.000 claims description 8
125000003118 aryl group Chemical group 0.000 claims description 6
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 6
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 6
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
229920002554 vinyl polymer Polymers 0.000 claims description 6
125000003545 alkoxy group Chemical group 0.000 claims description 5
229940030600 antihypertensive agent Drugs 0.000 claims description 5
239000002220 antihypertensive agent Substances 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
KOFKPEOVIYWXTC-UHFFFAOYSA-N benzyl diazepine-1-carboxylate Chemical compound C1=CC=CC=NN1C(=O)OCC1=CC=CC=C1 KOFKPEOVIYWXTC-UHFFFAOYSA-N 0.000 claims description 2
150000001721 carbon Chemical group 0.000 claims description 2
229940125782 compound 2 Drugs 0.000 claims description 2
GUGCLZQUEANZKP-UHFFFAOYSA-N OC(=O)C1=NNC=CC=C1 Chemical compound OC(=O)C1=NNC=CC=C1 GUGCLZQUEANZKP-UHFFFAOYSA-N 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
125000005192 alkyl ethylene group Chemical group 0.000 claims 1
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 1
125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 1
229920006395 saturated elastomer Polymers 0.000 abstract description 8
229910052717 sulfur Inorganic materials 0.000 abstract description 3
239000003814 drug Substances 0.000 abstract description 2
239000008194 pharmaceutical composition Substances 0.000 abstract description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
229910052757 nitrogen Inorganic materials 0.000 abstract 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
230000003276 anti-hypertensive effect Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 138
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 103
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 85
239000000243 solution Substances 0.000 description 59
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 54
VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 44
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
238000006243 chemical reaction Methods 0.000 description 30
239000007787 solid Substances 0.000 description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
239000000741 silica gel Substances 0.000 description 20
229910002027 silica gel Inorganic materials 0.000 description 20
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
239000003921 oil Substances 0.000 description 15
235000019198 oils Nutrition 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
239000003054 catalyst Substances 0.000 description 14
239000000706 filtrate Substances 0.000 description 14
230000008018 melting Effects 0.000 description 14
238000002844 melting Methods 0.000 description 14
150000001732 carboxylic acid derivatives Chemical class 0.000 description 13
239000011347 resin Substances 0.000 description 13
229920005989 resin Polymers 0.000 description 13
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 11
239000003960 organic solvent Substances 0.000 description 11
238000004587 chromatography analysis Methods 0.000 description 10
229910052943 magnesium sulfate Inorganic materials 0.000 description 10
235000019341 magnesium sulphate Nutrition 0.000 description 10
239000002904 solvent Substances 0.000 description 10
239000007858 starting material Substances 0.000 description 10
239000013078 crystal Substances 0.000 description 9
229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
235000017557 sodium bicarbonate Nutrition 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
239000012074 organic phase Substances 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
230000007017 scission Effects 0.000 description 8
229910000029 sodium carbonate Inorganic materials 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 7
238000000354 decomposition reaction Methods 0.000 description 7
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 7
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
OJUAMMUUNWSYLW-QMMMGPOBSA-N (3s)-3,9-dihydropyrazolo[1,2-a]diazepine-3-carboxylic acid Chemical compound C1C=CC=CN2[C@H](C(=O)O)C=CN21 OJUAMMUUNWSYLW-QMMMGPOBSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000010828 elution Methods 0.000 description 6
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
238000003756 stirring Methods 0.000 description 6
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
PPKAIMDMNWBOKN-UHFFFAOYSA-N 2-Oxo-4-phenylbutyric acid Chemical compound OC(=O)C(=O)CCC1=CC=CC=C1 PPKAIMDMNWBOKN-UHFFFAOYSA-N 0.000 description 5
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 5
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
239000002585 base Substances 0.000 description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
239000011230 binding agent Substances 0.000 description 5
238000009903 catalytic hydrogenation reaction Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
230000008020 evaporation Effects 0.000 description 5
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
229910000041 hydrogen chloride Inorganic materials 0.000 description 5
230000003993 interaction Effects 0.000 description 5
150000007530 organic bases Chemical class 0.000 description 5
230000008569 process Effects 0.000 description 5
239000000047 product Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000000284 extract Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
238000010992 reflux Methods 0.000 description 4
238000007363 ring formation reaction Methods 0.000 description 4
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
150000008041 alkali metal carbonates Chemical class 0.000 description 3
150000001540 azides Chemical class 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
125000004744 butyloxycarbonyl group Chemical group 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
CRGRWBQSZSQVIE-UHFFFAOYSA-N diazomethylbenzene Chemical compound [N-]=[N+]=CC1=CC=CC=C1 CRGRWBQSZSQVIE-UHFFFAOYSA-N 0.000 description 3
239000003480 eluent Substances 0.000 description 3
STPXIOGYOLJXMZ-UHFFFAOYSA-N ethyl 2-oxo-4-phenylbutanoate Chemical compound CCOC(=O)C(=O)CCC1=CC=CC=C1 STPXIOGYOLJXMZ-UHFFFAOYSA-N 0.000 description 3
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
238000007327 hydrogenolysis reaction Methods 0.000 description 3
239000003456 ion exchange resin Substances 0.000 description 3
229920003303 ion-exchange polymer Polymers 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000155 melt Substances 0.000 description 3
GIHODXXNWIRGMT-UHFFFAOYSA-N methyl diazepine-1-carboxylate Chemical compound COC(=O)N1C=CC=CC=N1 GIHODXXNWIRGMT-UHFFFAOYSA-N 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
108010064733 Angiotensins Proteins 0.000 description 2
102000015427 Angiotensins Human genes 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
RKOTXQYWCBGZLP-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-2-ethyl-9-hydroxy-3-methoxy-1,8-dioxospiro[3H-pyrido[1,2-a]pyrazine-4,3'-oxolane]-7-carboxamide Chemical compound CCN1C(OC)C2(CCOC2)N2C=C(C(=O)NCC3=C(F)C=C(F)C=C3)C(=O)C(O)=C2C1=O RKOTXQYWCBGZLP-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000008044 alkali metal hydroxides Chemical class 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000006260 foam Substances 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000008057 potassium phosphate buffer Substances 0.000 description 2
239000010970 precious metal Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
229910052703 rhodium Inorganic materials 0.000 description 2
239000010948 rhodium Substances 0.000 description 2
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
WRCLKWXNSKBMRP-LURJTMIESA-N (3S)-5,9-dioxo-1,2,3,6,7,8-hexahydropyrazolo[1,2-a]diazepine-3-carboxylic acid Chemical compound OC([C@H](CC1)N(C(CCC2)=O)N1C2=O)=O WRCLKWXNSKBMRP-LURJTMIESA-N 0.000 description 1
GOWDIAQQBRKSJH-RYUDHWBXSA-N (3s,6s)-6-(1,3-dioxoisoindol-2-yl)-5,9-dioxo-1,2,3,6,7,8-hexahydropyrazolo[1,2-a]diazepine-3-carboxylic acid Chemical compound C([C@H]1C(=O)O)CN(C(CC2)=O)N1C(=O)[C@H]2N1C(=O)C2=CC=CC=C2C1=O GOWDIAQQBRKSJH-RYUDHWBXSA-N 0.000 description 1
NPLGEEVZJGFJAO-WDSKDSINSA-N (3s,6s)-6-amino-5,9-dioxo-1,2,3,6,7,8-hexahydropyrazolo[1,2-a]diazepine-3-carboxylic acid Chemical compound O=C1[C@@H](N)CCC(=O)N2CC[C@@H](C(O)=O)N21 NPLGEEVZJGFJAO-WDSKDSINSA-N 0.000 description 1
DOUUPKDLDFXKDX-UHFFFAOYSA-N 1-o-benzyl 3-o-tert-butyl diazinane-1,3-dicarboxylate Chemical compound N1C(C(=O)OC(C)(C)C)CCCN1C(=O)OCC1=CC=CC=C1 DOUUPKDLDFXKDX-UHFFFAOYSA-N 0.000 description 1
ZYBMAAOZXXKYTG-UHFFFAOYSA-N 1-phenylmethoxycarbonyldiazinane-3-carboxylic acid Chemical compound N1C(C(=O)O)CCCN1C(=O)OCC1=CC=CC=C1 ZYBMAAOZXXKYTG-UHFFFAOYSA-N 0.000 description 1
NQIBQILAMKZKFE-UHFFFAOYSA-N 2-(5-bromo-2-fluorophenyl)-3-fluoropyridine Chemical compound FC1=CC=C(Br)C=C1C1=NC=CC=C1F NQIBQILAMKZKFE-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
OJUAMMUUNWSYLW-UHFFFAOYSA-N 3,9-dihydropyrazolo[1,2-a]diazepine-3-carboxylic acid Chemical compound C1C=CC=CN2C(C(=O)O)C=CN21 OJUAMMUUNWSYLW-UHFFFAOYSA-N 0.000 description 1
DEEPVUMBLJVOEL-UHFFFAOYSA-N 3H-pyrazole Chemical compound C1C=CN=N1 DEEPVUMBLJVOEL-UHFFFAOYSA-N 0.000 description 1
CIBNXHHWVVKRDY-UHFFFAOYSA-N 5-methyl-2-oxohexanoic acid Chemical compound CC(C)CCC(=O)C(O)=O CIBNXHHWVVKRDY-UHFFFAOYSA-N 0.000 description 1
MJXXAPORLGKVLB-UHFFFAOYSA-N 5-phenyl-2-keto-valeric acid Chemical compound OC(=O)C(=O)CCCC1=CC=CC=C1 MJXXAPORLGKVLB-UHFFFAOYSA-N 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
241001602876 Nata Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
OJUAMMUUNWSYLW-MRVPVSSYSA-N OC([C@@H]1N(C=CC=CC2)N2C=C1)=O Chemical compound OC([C@@H]1N(C=CC=CC2)N2C=C1)=O OJUAMMUUNWSYLW-MRVPVSSYSA-N 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000001785 acacia senegal l. willd gum Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
238000009635 antibiotic susceptibility testing Methods 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
AWYNYGDVTNSMIS-UHFFFAOYSA-N ethanamine;ethanol Chemical compound CCN.CCO AWYNYGDVTNSMIS-UHFFFAOYSA-N 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
UDJNHUAEPSYCRU-LLVKDONJSA-N ethyl (2r)-4-phenyl-2-(trifluoromethylsulfonyloxy)butanoate Chemical compound CCOC(=O)[C@H](OS(=O)(=O)C(F)(F)F)CCC1=CC=CC=C1 UDJNHUAEPSYCRU-LLVKDONJSA-N 0.000 description 1
ZLZXSWNRZFMSSS-UHFFFAOYSA-N ethyl 2-bromo-4-phenylbutanoate Chemical compound CCOC(=O)C(Br)CCC1=CC=CC=C1 ZLZXSWNRZFMSSS-UHFFFAOYSA-N 0.000 description 1
SXZHDULBCLKRAE-UHFFFAOYSA-N ethyl 2-bromo-5-methylhexanoate Chemical compound CCOC(=O)C(Br)CCC(C)C SXZHDULBCLKRAE-UHFFFAOYSA-N 0.000 description 1
RNKJLNWXMDLRLO-UHFFFAOYSA-N ethyl 2-oxo-4-(2-phenylphenyl)butanoate Chemical compound CCOC(=O)C(=O)CCC1=CC=CC=C1C1=CC=CC=C1 RNKJLNWXMDLRLO-UHFFFAOYSA-N 0.000 description 1
VUMFPMBWHQNWKS-UHFFFAOYSA-N ethyl 4-(4-chlorophenyl)-2-oxobutanoate Chemical compound CCOC(=O)C(=O)CCC1=CC=C(Cl)C=C1 VUMFPMBWHQNWKS-UHFFFAOYSA-N 0.000 description 1
YBQMIWIQGUAOTP-UHFFFAOYSA-N ethyl 4-(4-methoxyphenyl)-2-oxobutanoate Chemical compound CCOC(=O)C(=O)CCC1=CC=C(OC)C=C1 YBQMIWIQGUAOTP-UHFFFAOYSA-N 0.000 description 1
XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
DKXXCWZOOOIURS-UHFFFAOYSA-N ethyl diazepine-1-carboxylate Chemical compound CCOC(=O)N1C=CC=CC=N1 DKXXCWZOOOIURS-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910000510 noble metal Inorganic materials 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000003431 oxalo group Chemical group 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
229950009215 phenylbutanoic acid Drugs 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
ABWVLWHPVBHFLQ-UHFFFAOYSA-M sodium;2-oxo-3-phenylpropanoate;hydrate Chemical compound O.[Na+].[O-]C(=O)C(=O)CC1=CC=CC=C1 ABWVLWHPVBHFLQ-UHFFFAOYSA-M 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
239000010409 thin film Substances 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3886—Acids containing the structure -C(=X)-P(=X)(XH)2 or NC-P(=X)(XH)2, (X = O, S, Se)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/409—Compounds containing the structure P(=X)-X-acyl, P(=X) -X-heteroatom, P(=X)-X-CN (X = O, S, Se)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Health & Medical Sciences (AREA)
Crystallography & Structural Chemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)

BG098502A 1982-05-12 1994-02-21 Бициклични карбоксилни киселини и техни алкилни и аралкилни естери BG61123B2 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8213850		1982-05-12
GB08305505A GB2128984B (en)	1982-05-12	1983-02-28	Diaza-bicyclic compounds

Publications (1)

Publication Number	Publication Date
BG61123B2 true BG61123B2 (bg)	1996-11-29

Family

ID=26282820

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG098502A BG61123B2 (bg)	1982-05-12	1994-02-21	Бициклични карбоксилни киселини и техни алкилни и аралкилни естери

Country Status (32)

Country	Link
US (3)	US4512924A (fi)
EP (1)	EP0094095B1 (fi)
KR (1)	KR890002106B1 (fi)
AR (1)	AR240940A1 (fi)
AU (1)	AU567873B2 (fi)
BG (1)	BG61123B2 (fi)
CA (1)	CA1234568A (fi)
CS (2)	CS249128B2 (fi)
CU (1)	CU21532A3 (fi)
DE (2)	DE3317290A1 (fi)
DK (1)	DK160612C (fi)
DO (1)	DOP1983004163A (fi)
DZ (1)	DZ540A1 (fi)
ES (6)	ES8407049A1 (fi)
FI (1)	FI77244C (fi)
FR (1)	FR2531956B1 (fi)
GB (1)	GB2128984B (fi)
GR (1)	GR77462B (fi)
HK (1)	HK91692A (fi)
HU (3)	HU198935B (fi)
IE (1)	IE56480B1 (fi)
IL (1)	IL68620A (fi)
IT (1)	IT1212738B (fi)
LU (2)	LU84803A1 (fi)
MC (1)	MC1515A1 (fi)
MY (1)	MY102889A (fi)
NL (2)	NL8301640A (fi)
NO (1)	NO160368C (fi)
PT (1)	PT76681B (fi)
SE (1)	SE461792B (fi)
SG (1)	SG81192G (fi)
ZW (1)	ZW9883A1 (fi)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2128984B (en) *	1982-05-12	1985-05-22	Hoffmann La Roche	Diaza-bicyclic compounds
NZ204130A (en) *	1982-05-12	1986-03-14	Hoffmann La Roche	Bicyclic heterocyclic compounds and pharmaceutical compositions
DE3315464A1 (de) *	1983-04-28	1984-10-31	Hoechst Ag, 6230 Frankfurt	Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern
US4801721A (en) *	1984-08-16	1989-01-31	Ryan James W	Stereospecific synthesis of carboxyalkyl peptides
US4692438A (en) *	1984-08-24	1987-09-08	Hoffmann-La Roche Inc.	Pyridazo-diazepines, diazocines, and -triazepines having anti-hypertensive activity
US4826992A (en) *	1985-04-30	1989-05-02	Eli Lilly And Company	2,3-(Dihydro) bicyclic pyrazolidinones
ZA863170B (en) *	1985-04-30	1987-12-30	Lilly Co Eli	7-substituted bicyclic pyrazolidinones
US4940718A (en) *	1985-04-30	1990-07-10	Eli Lilly And Company	7-substituted bicyclic pyrazolidinones, pharmaceutical compositions and use
US4902707A (en) *	1985-04-30	1990-02-20	Eli Lilly And Company	Bicyclic pyrazolidinones, compositions and use
ZW11586A1 (en) *	1985-07-01	1987-12-30	Hoffmann La Roche	Bicyclic compounds
US4832763A (en) *	1985-10-15	1989-05-23	Westinghouse Electric Corp.	Method of stress-relief annealing a magnetic core containing amorphous material
DE3542794A1 (de) *	1985-12-04	1987-06-11	Bayer Ag	Antihypertensives kombinationspraeparat
EP0254032A3 (en) *	1986-06-20	1990-09-05	Schering Corporation	Neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0566157A1 (en)	1986-06-20	1993-10-20	Schering Corporation	Neutral metalloendopeptidase inhibitors in the treatment of hypertension
GB8629875D0 (en) *	1986-12-15	1987-01-28	Hoffmann La Roche	Pyridazodiazepine derivatives
US5262436A (en) *	1987-03-27	1993-11-16	Schering Corporation	Acylamino acid antihypertensives in the treatment of congestive heart failure
US4956490A (en) *	1989-03-09	1990-09-11	Merck & Co., Inc.	Process for preparing benzylpyruvic acids and esters
ZA902661B (en) *	1989-04-10	1991-01-30	Schering Corp	Mercapto-acyl amino acids
DE3917255A1 (de) *	1989-05-26	1990-11-29	Schopf Masch	Verfahren und vorrichtung zum aufnehmen eines flugzeugbugfahrwerks durch einen flugzeugschlepper
US5011938A (en) *	1989-10-02	1991-04-30	Eli Lilly And Company	7-substituted bicyclic pyrazolidinones
WO1991007386A1 (en) *	1989-11-21	1991-05-30	Schering Corporation	Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
AU7168091A (en) *	1989-12-22	1991-07-24	Schering Corporation	Mercaptocycloacyl aminoacid endopeptidase inhibitors
US5075302A (en) *	1990-03-09	1991-12-24	Schering Corporation	Mercaptoacyl aminolactam endopeptidase inhibitors
US5173506A (en) *	1990-08-16	1992-12-22	Schering Corporation	N-(mercaptoalkyl)ureas and carbamates
DE59107840D1 (de) *	1990-11-21	1996-06-27	Ciba Geigy Ag	Silylierte Acylphosphinoxide
US5208230A (en) *	1990-12-21	1993-05-04	Merrell Dow Pharmaceuticals	Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
ATE139768T1 (de) *	1991-03-19	1996-07-15	Ciba Geigy Ag	Verbindungen mit herbiziden,acarizider und insektizider wirkung
TW216770B (fi) *	1991-07-23	1993-12-01	Hoffmann La Roche
CA2078759C (en) *	1991-09-27	2003-09-16	Alan M. Warshawsky	Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
US5455242A (en) *	1991-09-27	1995-10-03	Merrell Dow Pharmaceuticals Inc.	Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
US5457196A (en) *	1991-09-27	1995-10-10	Merrell Dow Pharmaceuticals Inc.	2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
JPH06107661A (ja) *	1991-10-24	1994-04-19	Upjohn Co:The	イミダゾール誘導体およびこれを有効成分とする医薬組成物
US5442062A (en) *	1991-10-24	1995-08-15	The Upjohn Company	Imidazole derivatives and pharmaceutical compositions containing the same
US5972990A (en) *	1992-04-10	1999-10-26	Brigham And Women's Hospital, Inc.	Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5977160A (en) *	1992-04-10	1999-11-02	Brigham And Women's Hospital, Inc.	Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5552397A (en) *	1992-05-18	1996-09-03	E. R. Squibb & Sons, Inc.	Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
WO1993023403A1 (en) *	1992-05-15	1993-11-25	Merrell Dow Pharmaceuticals Inc.	NOVEL MERCAPTOACETYLAMIDO PYRIDAZO[1,2]PYRIDAZINE, PYRAZOLO[1,2]PYRIDAZINE, PYRIDAZO[1,2-a][1,2]DIAZEPINE AND PYRAZOLO[1,2-a][1,2]DIAZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE
EP0570764B1 (de) *	1992-05-18	2001-07-18	F.Hoffmann-La Roche & Co. Aktiengesellschaft	Asymmetrische Hydrierung
US5238932A (en) *	1992-05-20	1993-08-24	Merrell Dow Pharmaceuticals Inc.	Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
NZ256589A (en) *	1992-10-30	1996-05-28	Merrell Dow Pharma	Condensed azepine analogues and medicaments (where a is c, o or s and b is o or s)
JPH072859A (ja) *	1993-01-28	1995-01-06	Upjohn Co:The	ピラゾール誘導体およびこれを有効成分とする医薬組成物
US5476395A (en) *	1993-03-01	1995-12-19	Methode Electronics, Inc.	Planar fuse panel
US5654294A (en) *	1993-05-13	1997-08-05	Bristol-Myers Squibb	Spiro lactam dual action inhibitors
DE59409631D1 (de) *	1993-07-15	2001-02-15	Hoffmann La Roche	Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
PT750631E (pt) *	1994-02-14	2000-07-31	Merrell Pharma Inc	Novos derivados de dissulfureto de mercapto-aacetilamido-1,3,4,5-tetra-hidro-benzo¬c)azepin-3-ona uteis como inibidores de encefalinase e ace
CA2183314C (en) *	1994-02-14	1999-08-31	Gary A. Flynn	Novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
DE69416873T2 (de) *	1994-02-14	1999-07-29	Merrell Pharmaceuticals Inc., Cincinnati, Ohio	Mercaptoacetylamid disulfidderivate als enkephalinase und ace inhibitoren
US5530013A (en) *	1994-02-14	1996-06-25	American Home Products Corporation	Venlafaxine in the inducement of cognition enhancement
HUT74584A (en) *	1994-02-14	1997-01-28	Merrell Pharma Inc	Novel heterocycle fused benzazepine-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase, process for producing them and pharmaceutical compositions containing them
US5484783A (en) *	1994-03-24	1996-01-16	Merrell Dow Pharmaceuticals Inc.	Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
DE69514912T2 (de) *	1994-03-24	2000-10-05	Merrell Pharmaceuticals Inc., Cincinnati	Hypocholesterolemische, antiatherosklerotische und hypotriglyceridemische verwendung von aminoacetylmercapto derivaten
DK0751774T3 (da) *	1994-03-24	2003-12-08	Merrell Pharma Inc	Hypocholesterolæmiske mercaptoacetylamiddisulfid-derivater
US5756466A (en)	1994-06-17	1998-05-26	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
US5587375A (en) *	1995-02-17	1996-12-24	Bristol-Myers Squibb Company	Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) *	1995-05-17	1999-03-02	Bristol-Myers Squibb	Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5650408A (en) *	1995-06-07	1997-07-22	Karanewsky; Donald S.	Thiazolo benzazepine containing dual action inhibitors
US5635504A (en) *	1995-06-07	1997-06-03	Bristol-Myers Squibb Co.	Diazepine containing dual action inhibitors
FR2777889B1 (fr) *	1998-04-27	2004-07-09	Hoechst Marion Roussel Inc	Nouveaux derives de l'acide octahydro-6,10-dioxo-6h- pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de composes therapeutiquement actifs
AU2003200034B2 (en) *	1998-04-27	2006-07-20	Aventis Pharma S.A.	New derivatives of octahydro-6, 10-dioxo-6H-pyridazino [1,2-A][1,2]diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds
FR2777888B1 (fr) *	1998-04-27	2004-07-16	Hoechst Marion Roussel Inc	Nouveaux derives de l'acide (3,4,7,8,9,10-hexahydro-6,10- dioxo-6h-pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de medicaments
US6703500B2 (en)	1998-08-19	2004-03-09	Vertex Pharmaceuticals, Incorporated	Method of preparing bicyclic intermediates from piperazic acid or an ester thereof useful in the manufacture of caspase inhibitors
US6177565B1 (en) *	1998-08-19	2001-01-23	Vertex Pharmaceuticals Inc.	Process for synthesizing piperazic acid
US6559304B1 (en) *	1998-08-19	2003-05-06	Vertex Pharmaceuticals Incorporated	Method for synthesizing caspase inhibitors
FR2788276B1 (fr) *	1999-01-12	2001-02-16	Hoechst Marion Roussel Inc	NOUVEAU PROCEDE DE PREPARATION DE COMPOSES BICYCLIQUES ET L'APPLICATION DE CE PROCEDE COMME ETAPE INTERMEDIAIRE POUR LA PREPARATION D'UN COMPOSE INHIBITEUR DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1-BETA (ice)
EP1216037A2 (en) *	1999-09-21	2002-06-26	Emory University	Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US20030113330A1 (en) *	1999-11-08	2003-06-19	Uhal Bruce D.	Methods for treating pulmonary fibrosis
US8101363B2 (en)	2000-12-14	2012-01-24	The Brigham And Women's Hospital, Inc.	Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
GB0119305D0 (en)	2001-04-12	2001-10-03	Aventis Pharma Gmbh	Mercaptoacetylamide derivatives,a process for their preparation and their use
CA2484897C (en)	2002-05-09	2015-10-06	The Brigham And Women's Hospital, Inc.	Soluble st2 as a cardiovascular disease marker and therapeutic target
US20040110241A1 (en) *	2002-12-06	2004-06-10	Segal Mark S.	Materials and methods for monitoring vascular endothelial function
EP1585500B8 (en)	2002-12-20	2017-07-26	Auritec Pharmaceuticals	Coated particles for sustained-release pharmaceutical administration
EP1603916A1 (en) *	2003-03-06	2005-12-14	Ranbaxy Laboratories, Ltd.	Enantiomerically pure cilazapril, process for preparation
WO2005003134A1 (en) *	2003-07-07	2005-01-13	Hetero Drugs Limited	A novel process for the preparation of cilazapril
AU2004315596B2 (en)	2003-08-29	2011-11-24	President And Fellows Of Harvard College	Inhibitors of cellular necrosis
JP4625812B2 (ja)	2003-12-05	2011-02-02	ザクリーブランドクリニックファウンデーション	心臓血管疾患に対するリスクマーカー
US7803838B2 (en) *	2004-06-04	2010-09-28	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
WO2005122682A2 (en)	2004-06-18	2005-12-29	Ranbaxy Laboratories Limited	Process for the preparation of esters of piperazic acid
WO2006042192A2 (en)	2004-10-06	2006-04-20	The Brigham And Womens's Hospital, Inc.	Relevance of achieved levels of markers of systemic inflammation following treatment
AU2006206249A1 (en) *	2005-01-21	2006-07-27	Nicox S.A.	Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
NZ560386A (en) *	2005-01-31	2009-12-24	Mylan Lab Inc	Pharmaceutical composition comprising hydroxylated nebivolol
EP2174658A1 (en)	2005-05-31	2010-04-14	Mylan Laboratories, Inc	Compositions comprising nebivolol
US8119358B2 (en)	2005-10-11	2012-02-21	Tethys Bioscience, Inc.	Diabetes-related biomarkers and methods of use thereof
DK1864677T3 (da)	2006-06-02	2008-04-28	Teva Pharma	Stabil formulering omfattende et fugtsensitivt lægemiddel og fremstillingsmetoder deraf
US20070281000A1 (en) *	2006-06-02	2007-12-06	Michael Fox	Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
CA2659082A1 (en)	2006-06-07	2007-12-21	Tethys Bioscience, Inc.	Markers associated with arteriovascular events and methods of use thereof
US20080008751A1 (en) *	2006-07-10	2008-01-10	Michael Fox	Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
TW200849035A (en)	2007-04-18	2008-12-16	Tethys Bioscience Inc	Diabetes-related biomarkers and methods of use thereof
US7828840B2 (en) *	2007-11-15	2010-11-09	Med Institute, Inc.	Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
GB2460915B (en)	2008-06-16	2011-05-25	Biovascular Inc	Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2221299A3 (en)	2009-02-11	2010-11-03	Dr. Reddy's Laboratories Ltd.	Preparation of cilazapril intermediates
JP2013518618A (ja)	2010-02-01	2013-05-23	ザ・ホスピタル・フォー・シック・チルドレン	再狭窄を治療および予防するための遠隔虚血コンディショニング
KR20190000368A (ko)	2010-03-31	2019-01-02	더 호스피탈 포 식 칠드런	심근 경색 후 결과를 개선시키기 위한 원격 허혈 처치의 사용
EP2555692A2 (en)	2010-04-08	2013-02-13	The Hospital For Sick Children	Use of remote ischemic conditioning for traumatic injury
WO2012049646A1 (en)	2010-10-12	2012-04-19	Ranbaxy Laboratories Limited	Process for the preparation of an intermediate of cilazapril
EP2537534B1 (en)	2011-06-22	2014-12-17	Hexal AG	Esters of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their therapeutic use.
BR112014001283A2 (pt)	2011-07-18	2017-02-21	Critical Care Diagnostics Inc	métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício
SG11201407402TA (en)	2012-05-11	2014-12-30	Reset Therapeutics Inc	Carbazole-containing sulfonamides as cryptochrome modulators
AU2013296803B2 (en)	2012-08-01	2018-03-08	Eric Ostertag	Free flowing, frozen compositions comprising a therapeutic agent
WO2014145022A1 (en)	2013-03-15	2014-09-18	President And Fellows Of Harvard College	Hybrid necroptosis inhibitors
KR102069473B1 (ko)	2013-03-21	2020-01-22	유프락시아 파마수티컬스 유에스에이 엘엘씨	주입가능한 서방성 방출 조성물 및 관절 내 염증 및 이와 관련된 통증을 치료하기 위해 이를 사용하는 방법
TWI690521B (zh)	2014-04-07	2020-04-11	美商同步製藥公司	作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
TR201808237T4 (tr)	2015-10-27	2018-07-23	Eupraxia Pharmaceuticals Inc	Lokal anestetiklerin sürekli salım formülasyonları.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL58849A (en) *	1978-12-11	1983-03-31	Merck & Co Inc	Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
IL60617A0 (en) *	1979-07-23	1980-09-16	Sparamedica Ag	Triazolopyridazine derivative,their preparation and pharmaceutical compositions containing them
DE3062972D1 (en) *	1979-09-19	1983-06-09	Hoffmann La Roche	Pyridazopyridazine derivatives, processes for their preparation and pharmaceutical compositions containing these pyridazopyridazine derivatives
EP0042100A1 (de) *	1980-06-13	1981-12-23	F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft	Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel
DE3169261D1 (en) *	1980-09-10	1985-04-18	Beecham Group Plc	Aryl diazabicyclyl amides, a process for their preparation and use
GB2128984B (en) *	1982-05-12	1985-05-22	Hoffmann La Roche	Diaza-bicyclic compounds

1983
- 1983-02-28 GB GB08305505A patent/GB2128984B/en not_active Expired
- 1983-04-29 ZW ZW98/83A patent/ZW9883A1/xx unknown
- 1983-04-29 CA CA000427095A patent/CA1234568A/en not_active Expired
- 1983-05-02 DK DK194783A patent/DK160612C/da not_active IP Right Cessation
- 1983-05-06 IL IL68620A patent/IL68620A/xx not_active IP Right Cessation
- 1983-05-09 HU HU875410A patent/HU198935B/hu unknown
- 1983-05-09 NL NL8301640A patent/NL8301640A/nl not_active Application Discontinuation
- 1983-05-09 HU HU831589A patent/HU195965B/hu unknown
- 1983-05-09 CU CU8335899A patent/CU21532A3/xx unknown
- 1983-05-09 IT IT8321000A patent/IT1212738B/it active
- 1983-05-09 AU AU14364/83A patent/AU567873B2/en not_active Expired
- 1983-05-09 HU HU875409A patent/HU199842B/hu not_active IP Right Cessation
- 1983-05-10 DZ DZ836846A patent/DZ540A1/fr active
- 1983-05-10 MC MC821633A patent/MC1515A1/xx unknown
- 1983-05-10 FR FR8307785A patent/FR2531956B1/fr not_active Expired
- 1983-05-11 NO NO831675A patent/NO160368C/no not_active IP Right Cessation
- 1983-05-11 DE DE19833317290 patent/DE3317290A1/de not_active Ceased
- 1983-05-11 CS CS833303A patent/CS249128B2/cs unknown
- 1983-05-11 ES ES522291A patent/ES8407049A1/es not_active Expired
- 1983-05-11 EP EP83104668A patent/EP0094095B1/de not_active Expired - Lifetime
- 1983-05-11 IE IE1084/83A patent/IE56480B1/en not_active IP Right Cessation
- 1983-05-11 AR AR292991A patent/AR240940A1/es active
- 1983-05-11 LU LU84803A patent/LU84803A1/de unknown
- 1983-05-11 DE DE8383104668T patent/DE3381884D1/de not_active Expired - Lifetime
- 1983-05-11 KR KR1019830002033A patent/KR890002106B1/ko not_active IP Right Cessation
- 1983-05-11 SE SE8302716A patent/SE461792B/sv not_active IP Right Cessation
- 1983-05-12 US US06/493,876 patent/US4512924A/en not_active Expired - Lifetime
- 1983-05-12 DO DO1983004163A patent/DOP1983004163A/es unknown
- 1983-05-12 FI FI831661A patent/FI77244C/fi not_active IP Right Cessation
- 1983-05-12 PT PT76681A patent/PT76681B/pt unknown
- 1983-05-12 GR GR71331A patent/GR77462B/el unknown
1984
- 1984-01-02 ES ES528625A patent/ES8505173A1/es not_active Expired
- 1984-01-02 ES ES528627A patent/ES8601994A1/es not_active Expired
- 1984-01-02 ES ES528628A patent/ES8706672A1/es not_active Expired
- 1984-01-02 ES ES528630A patent/ES8607970A1/es not_active Expired
1985
- 1985-02-01 US US06/697,559 patent/US4658024A/en not_active Expired - Lifetime
1986
- 1986-05-14 ES ES554935A patent/ES8800170A1/es not_active Expired
- 1986-11-28 US US06/936,003 patent/US4772701A/en not_active Expired - Lifetime
1987
- 1987-09-08 MY MYPI87001597A patent/MY102889A/en unknown
1991
- 1991-12-23 CS CS914021A patent/CS402191A3/cs unknown
1992
- 1992-08-12 SG SG811/92A patent/SG81192G/en unknown
- 1992-11-19 HK HK916/92A patent/HK91692A/xx not_active IP Right Cessation
1993
- 1993-06-09 LU LU88299C patent/LU88299I2/fr unknown
- 1993-06-11 NL NL930055C patent/NL930055I2/nl unknown
1994
- 1994-02-21 BG BG098502A patent/BG61123B2/bg unknown

Also Published As

Publication number	Publication date
PT76681B (en)	1986-05-20
NL930055I1 (nl)	1993-09-01
DK160612B (da)	1991-04-02
IL68620A (en)	1987-11-30
ES528630A0 (es)	1986-06-16
ES528627A0 (es)	1985-11-16
SE461792B (sv)	1990-03-26
ES528625A0 (es)	1985-05-16
FI77244B (fi)	1988-10-31
SE8302716L (sv)	1983-11-13
DK194783D0 (da)	1983-05-02
LU84803A1 (fr)	1985-03-21
CS402191A3 (en)	1992-10-14
EP0094095A3 (en)	1984-11-21
DE3381884D1 (de)	1990-10-25
HU195965B (en)	1988-08-29
DOP1983004163A (es)	1988-09-20
AU567873B2 (en)	1987-12-10
IT1212738B (it)	1989-11-30
GB2128984A (en)	1984-05-10
ES8601994A1 (es)	1985-11-16
DE3317290A1 (de)	1983-11-17
IL68620A0 (en)	1983-09-30
CA1234568A (en)	1988-03-29
IT8321000A0 (it)	1983-05-09
US4658024A (en)	1987-04-14
DK160612C (da)	1991-09-23
ES8706672A1 (es)	1987-07-16
ES8800170A1 (es)	1987-11-01
PT76681A (en)	1983-06-01
EP0094095A2 (de)	1983-11-16
HU199842B (en)	1990-03-28
FR2531956A1 (fr)	1984-02-24
FI831661A0 (fi)	1983-05-12
ES522291A0 (es)	1984-08-16
HU198935B (en)	1989-12-28
DK194783A (da)	1983-11-13
GB2128984B (en)	1985-05-22
MY102889A (en)	1993-03-31
GR77462B (fi)	1984-09-24
NL930055I2 (nl)	1993-10-01
US4512924A (en)	1985-04-23
IE831084L (en)	1983-11-12
DZ540A1 (fr)	2004-09-13
FI77244C (fi)	1989-02-10
SG81192G (en)	1993-01-29
AR240940A1 (es)	1991-03-27
ES8407049A1 (es)	1984-08-16
US4772701A (en)	1988-09-20
CS249128B2 (en)	1987-03-12
ZW9883A1 (en)	1984-11-21
AR240940A2 (es)	1991-03-27
KR890002106B1 (ko)	1989-06-19
NO160368C (no)	1989-04-12
HK91692A (en)	1992-11-27
AU1436483A (en)	1983-11-17
CU21532A3 (en)	1987-06-09
FI831661L (fi)	1983-11-13
NO831675L (no)	1983-11-14
NL8301640A (nl)	1983-12-01
SE8302716D0 (sv)	1983-05-11
LU88299I2 (fr)	1994-09-09
FR2531956B1 (fr)	1987-02-20
ES554935A0 (es)	1987-11-01
ES8607970A1 (es)	1986-06-16
NO160368B (no)	1989-01-02
EP0094095B1 (de)	1990-09-19
IE56480B1 (en)	1991-08-14
KR840004754A (ko)	1984-10-24
ES8505173A1 (es)	1985-05-16
ES528628A0 (es)	1987-07-16
MC1515A1 (fr)	1984-02-10
GB8305505D0 (en)	1983-03-30

Publication	Publication Date	Title
BG61123B2 (bg)	1996-11-29	Бициклични карбоксилни киселини и техни алкилни и аралкилни естери
US4808713A (en)	1989-02-28	Anthypertensive pyridazo [1,2-a][1,2]diazepines
US4762924A (en)	1988-08-09	Bicyclic compounds
US4399136A (en)	1983-08-16	Pyrazolopyridazine antihypertensives
EP0565721B1 (en)	1995-07-26	1,4-benzothiazepine derivative
US4757069A (en)	1988-07-12	Pyridazodiazepine derivatives
PT90659B (pt)	1994-10-31	Processo para a preparacao de inibidores de renina contendo diois
CZ104595A3 (en)	1996-02-14	Derivatives of hydroxamic acid with tricyclic substituents
US3586683A (en)	1971-06-22	2,5(5) - di(tri)substituted - 10b-hydroxy-3,6 - dioxo-octahydro-oxazolo(3,2-a) pyrrolo(2,1-c)pyrazine derivatives of lysergic acid
US4225495A (en)	1980-09-30	Pyrrolo or pyrido [2,1-c][1,4] thiazines or thiazepines
IE61548B1 (en)	1994-11-16	Non-peptidic renin inhibitors
HU192914B (en)	1987-07-28	Process for producing new 3-/substituted amino/-5-phenyl-2/3h/-furanone derivatives and pharmaceutically acceptable salts
FI81580C (fi)	1990-11-12	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara pyridazopyridazinderivat och nya mellanprodukter.
CZ280148B6 (cs)	1995-11-15	Anelované deriváty azepinonu a azocinonu, způsob jejich výroby a farmaceutický prostředek je obsahující
EP0508004A1 (en)	1992-10-14	Phenylsulfonylalkanoic acid compounds
CS250699B2 (en)	1987-05-14	Method of octahydro-6-azaindole's depetidic derivatives production